At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Bicalutamide, Laboratory Biomarker Analysis, and 2 other interventions for Hormone-Resistant Prostate Cancer and Recurrent Prostate Carcinoma. Completed, enrolled 23 participants across 6 sites.
Detailed Summary
This randomized phase II trial is studying how well giving pazopanib with or without bicalutamide works in treating patients with prostate cancer that did not respond to hormone therapy. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Giving pazopanib hydrochloride together with bicalutamide may be an effective treatment for prostate cancer.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given PO
Correlative studies